Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.39 USD | +1.11% | +1.85% | -29.10% |
May. 15 | Transcript : STRATA Skin Sciences, Inc., Q1 2024 Earnings Call, May 15, 2024 | |
May. 15 | Earnings Flash (SSKN) STRATA SKIN SCIENCES Reports Q1 Revenue $6.8M, vs. Street Est of $6.9M | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-29.10% | 13.52M | - | ||
+11.18% | 227B | B | ||
+15.22% | 198B | B- | ||
+19.19% | 142B | B- | ||
+30.89% | 111B | A- | ||
+1.56% | 64.16B | A- | ||
+18.48% | 54.1B | B+ | ||
+5.12% | 51.41B | B+ | ||
+10.53% | 45.32B | A | ||
+5.98% | 37.32B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SSKN Stock
- Ratings STRATA Skin Sciences, Inc.